Our website uses cookies to distinguish you from other users of our website to provide you with the most relevant experience by remembering your preferences and repeat visits. By clicking on ‘Accept’ you consent to our cookie policy. However, you may visit ‘Cookie Settings’ to provide a controlled consent.

Accept

News

Archive

Ventyx Biosciences announces $27 million strategic investment from Sanofi PlanetiQ awarded $6.5 Million NOAA contract to supply Radio Occultation data for the commercial weather pilot data program Ventyx Biosciences announces initiation of dosing in a Phase 2a trial of VTX3232 in patients with early Parkinson’s disease Vascular Therapies completes enrollment in the ACCESS 2 study, a Phase III multinational randomized clinical trial of the Sirolimus Eluting Collagen Implant (Sirogen™) for the surgical creation of arteriovenous fistula for hemodialysis vascular access Ventyx Biosciences announces results from the Phase 2 trial of VTX958 in participants with moderately to severely active Crohn’s disease Emporos and InterLink AI Partner, develop only POS-Integrated lighted will-call solution
Back To News
Resolve Therapeutics
October 17, 2017

Resolve Therapeutics

Focused on the development of a biologic therapy for Lupus and Sjögren’s Syndrome.

Cookie Policy Website powered by 100% renewable energy Privacy Policy